# Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/promotional-labeling-and-advertising-considerations-for-prescription-biological-reference-and-biosimilar-products-questions-and-answers-guidance-for-industry/5c8b9c05-0acc-4e14-a3bd-6fdff92000ae

> FDA guidance document: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry. Issue date: April 24, 2024. Get complete insights and analysis.

---

## Details

- Title: Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry
- Communication Type: Guidance Document
- Product Type: other
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2024-04-24
- Comment Close Date: 2024-06-25
- Last Changed: 2024-04-25
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2019-D-5473">FDA-2019-D-5473</a>

## Related Documents

- [Labeling for Biosimilar and Interchangeable Biosimilar Products](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-biosimilar-and-interchangeable-biosimilar-products/54a5f712-03f5-4993-b0d7-6a1c2f261eff)
- [Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-manufacturing-changes-to-biosimilar-and-interchangeable-biosimilar-products-questions-and-answers/f791f37f-3382-48a9-8fcb-f27046ac94a4)
- [Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products —  Content and Format   Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/drug-abuse-and-dependence-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format-guidance-for-industry/e65bdb77-e74c-42d7-aab4-482af24834d1)